Fasting Plasma Glucose as a Primary Screening Test for the Diagnosis of Gestational Diabetes mellitus

Md. Rakibul Hasan; Nusrat Sultana; Sandesh Panthi; Mashfiqul Hasan; Sharmin Jahan; Yasmin Aktar; Muhammad Abul Hasanat

doi:10.1101/2024.08.23.24312519

Abstract

Aim To see the diagnostic efficacy of fasting plasma glucose (FPG) in respect to OGTT during pregnancy.

Materials and Method In this cross-sectional study, we enrolled 542 pregnant women 18 years or older by consecutive sampling irrespective of gestational age. 75gm three samples OGTT was done and categorized them to either normal glucose tolerance (NGT) or abnormal glucose tolerance (AGT) according to World Health Organization (WHO) 2013 criteria.

Results The sensitivity of FPG with a threshold of 5.1mmol/L was 47.3% among the study subjects, which was very low but specificity was very high (99.7%). However, changing the cut off value to 4.7mmo/L and 4.5mmol/L significantly increased the sensitivity to 64.8% and 73.3% with modestly decreased specificity to 86.2% and 73.2% respectively. In pregnant women with gestational age 24 to 28 weeks, FPG with a threshold of 4.5mmol/L could identify 75% of GDM subjects with specificity 76.8%. Furthermore, it has the highest sensitivity in detecting AGT in all three trimesters (80%, 74.4% and 68%) compared to 4.7mmol/L (80%, 68.9% and 50%) and 5.1 (80%, 47.8% and 30%) in 1^st, 2^nd and 3^rd trimester respectively. FPG had positive correlation with maternal age (r=0.138, p=0.001), BMI (r=0.164, p<0.001) but negative correlation with weeks of gestation (r= -0.242, p<0.001).

Conclusion FPG with cut off value of 4.5mmol/L may be used as an initial screening test for GDM to reduce the need for OGTT.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by University Research and Development, BSMMU

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Institutional Review Board (IRB) of BSMMU, Reg: No. BSMMU/2013/14269 and BSMMU/2016/2746

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

e-mail:nusrat_sultana{at}bsmmu.edu.bd
e-mail: sandesh20081{at}hotmail.com
e-mail: mashfiq.hasan{at}gmail.com
e-mail: sharmin.jahan{at}monash.edu.
e-mail: hasnat_endo{at}bsmmu.edu.bd

Data Availability

All data produced in the present study are available upon reasonable request to the authors

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.